[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "For this patient with decompensated alcoholic cirrhosis and variceal hemorrhage requiring multiple vasopressors, I need to consider the hemodynamic profile and best next step.\n\nThe patient has:\n- Hyperdynamic circulation (high ScvO2, hyperdynamic LV)\n- Underfilled status (low CVP, collapsible IVC)\n- Refractory shock despite high-dose norepinephrine and vasopressin\n- Ongoing organ dysfunction (renal failure, acidosis)\n\nOption A (Add epinephrine targeting higher MAP): Targeting higher MAP could further compromise splanchnic circulation and isn't supported by evidence in cirrhotic patients.\n\nOption B (Add dobutamine): Not indicated with already hyperdynamic circulation and high ScvO2.\n\nOption C (Add angiotensin II): Angiotensin II works through a different mechanism than catecholamines and vasopressin. In refractory vasodilatory shock, adding a vasopressor with a different mechanism of action is rational. It can help maintain MAP without excessive catecholamine doses.\n\nOption D (Increase vasopressin above 0.04 units/min): Exceeding the recommended maximum dose increases risk of splanchnic ischemia without proven benefit.\n\nOption E (Switch to phenylephrine): Would lose beneficial β1 effects of norepinephrine and potentially worsen splanchnic perfusion.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient with JAK2-positive polycythemia vera has developed post-polycythemia vera myelofibrosis, as evidenced by:\n\n1. Constitutional symptoms (fatigue, weight loss, night sweats)\n2. Massive splenomegaly\n3. Cytopenias (anemia, thrombocytopenia)\n4. Leukoerythroblastic blood picture with tear-drop cells\n5. Grade 3 reticulin fibrosis on bone marrow biopsy\n6. Atypical megakaryocytic clusters\n7. New complex karyotype with monosomy 7\n\nThe presence of monosomy 7 and a complex karyotype represents high-risk cytogenetic features. This patient has advanced myelofibrosis with poor prognostic features.\n\nLet's evaluate each option:\n\nA. Escalating hydroxyurea - Not appropriate as the disease has progressed beyond control with hydroxyurea\n\nB. Ruxolitinib - While JAK inhibitors can help with symptoms and splenomegaly in myelofibrosis, they are not curative and would be palliative in this high-risk patient\n\nC. Allogeneic stem cell transplantation - This is the only potentially curative option for myelofibrosis, particularly indicated in patients with high-risk features like this patient\n\nD. Azacitidine - Not standard first-line therapy for post-PV myelofibrosis\n\nE. Interferon - Not typically used for established myelofibrosis\n\nGiven the patient's high-risk features (complex karyotype with monosomy 7), allogeneic stem cell transplantation evaluation is the most appropriate next step for disease-modifying treatment.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with signs and symptoms highly suggestive of massive pulmonary embolism (PE) during pregnancy, including acute dyspnea, pleuritic chest pain, near syncope, tachycardia, hypotension, and hypoxemia. The bedside echo findings of RV dilation with McConnell sign (RV free wall hypokinesis with apical sparing) and septal flattening strongly support this diagnosis.\n\nThe patient is hemodynamically unstable (BP 82/48 mmHg) with evidence of right heart strain, indicating massive PE with obstructive shock. This is a life-threatening emergency requiring immediate reperfusion therapy.\n\nFor massive PE with hemodynamic instability, systemic thrombolysis is the standard of care, even during pregnancy, as the maternal benefit outweighs the risks. While pregnancy is a relative contraindication to thrombolysis, in this case of life-threatening PE, systemic thrombolysis with weight-based alteplase is appropriate.\n\nCatheter-directed thrombolysis would delay treatment and may not be rapidly available. Surgical embolectomy requires transfer and setup time that this unstable patient may not have. High-dose heparin alone without reperfusion therapy is inadequate for massive PE with shock. Tenecteplase is not the first-line thrombolytic for PE in pregnancy.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the correct diagnosis, I'll analyze the clinical presentation, examination findings, and diagnostic test results.\n\nKey findings:\n- 4-year-old boy with progressive leg weakness after viral URI\n- Flaccid symmetric weakness (legs > arms)\n- Areflexia\n- Intact sensation\n- No cranial nerve involvement\n- Respiratory compromise (FVC 55%)\n- Normal MRI spine\n- CSF: Mild protein elevation with normal cell count\n- NCS: Reduced CMAP amplitudes with preserved conduction velocities and distal latencies\n- Normal sensory studies\n- Absent F-waves\n\nThe pattern of predominantly motor involvement with normal sensory studies points to an axonal motor neuropathy. The preserved conduction velocities with reduced amplitudes is characteristic of axonal rather than demyelinating pathology.\n\nAMAN (option B) is characterized by:\n- Pure motor axonal degeneration\n- Normal sensory studies\n- Reduced CMAP amplitudes with preserved conduction velocities\n- Often follows Campylobacter jejuni infection or viral illness\n- Absent F-waves\n\nThis perfectly matches our patient's presentation. AMAN is a variant of Guillain-Barré syndrome with primarily axonal damage to motor nerves.\n\nThe other options don't fit as well:\n- AIDP would show slowed conduction velocities and prolonged distal latencies\n- AMSAN would show sensory nerve involvement\n- Miller Fisher syndrome presents with ataxia, ophthalmoplegia, and areflexia\n- Acute flaccid myelitis would typically show MRI abnormalities in the spinal cord\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most appropriate surgical approach for this patient, I need to analyze the clinical presentation and imaging findings.\n\nThe patient has:\n- A 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema\n- Contiguity with an opacified frontal sinus\n- Progressive neurological symptoms (confusion, left hemiparesis)\n- Papilledema indicating increased intracranial pressure\n- Failed outpatient antibiotic therapy\n\nThis presentation is consistent with a brain abscess secondary to frontal sinusitis. The size (3.5 cm), neurological deficits, and increased intracranial pressure indicate the need for immediate surgical intervention.\n\nOption A (CT-guided stereotactic aspiration) would be appropriate for smaller, deep abscesses but may not adequately address the sinus source.\n\nOption B (open craniotomy with complete abscess excision and sinus drainage) addresses both the intracranial abscess and the primary source of infection in the frontal sinus.\n\nOption C (endoscopic sinus drainage only) would not address the intracranial abscess.\n\nOption D (external ventricular drain) would only manage increased intracranial pressure without treating the abscess.\n\nOption E (delay surgery) would be inappropriate given the patient's deteriorating condition and the size of the abscess.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to assess the grade of pneumonitis and the appropriate management based on the clinical presentation.\n\nThe patient has:\n- Worsening exertional dyspnea and dry cough for 4 days\n- Oxygen saturation of 90% on room air\n- CT findings of bilateral ground-glass opacities and reticular changes\n- No evidence of infection, heart failure, or other causes\n- Recent pembrolizumab treatment (immune checkpoint inhibitor)\n\nThis presentation is consistent with immune checkpoint inhibitor-induced pneumonitis.\n\nGrading of pneumonitis:\n- Grade 1: Asymptomatic, radiographic findings only\n- Grade 2: Symptomatic, mild to moderate symptoms limiting instrumental ADLs\n- Grade 3: Severe symptoms limiting self-care ADLs, oxygen indicated\n- Grade 4: Life-threatening respiratory compromise\n- Grade 5: Death\n\nThe patient has symptoms (dyspnea, cough) and hypoxia (90% on room air), which indicates at least Grade 2 pneumonitis. The oxygen desaturation to 90% indicates the need for supplemental oxygen, which meets criteria for Grade 3 pneumonitis.\n\nManagement for Grade 3 pneumonitis includes:\n- Permanently discontinuing the immune checkpoint inhibitor\n- High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day)\n- Hospitalization for monitoring and supportive care\n\nInfliximab would only be considered if there's no improvement with steroids after 48-72 hours, not as first-line therapy without steroids.\n\nThe answer is (D)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the patient's presentation, diagnosis, and molecular classification.\n\nThe patient has a medulloblastoma with specific characteristics:\n- WNT-activated subtype with CTNNB1 mutation and monosomy 6\n- No metastatic disease\n- Near-total (not gross total) resection\n\nWNT-activated medulloblastoma is known to have the most favorable prognosis among medulloblastoma subtypes, with >90% survival rates. This favorable molecular profile allows for treatment de-escalation compared to other medulloblastoma subtypes.\n\nOption A (high-risk protocol) would be excessive for a WNT-activated tumor without metastasis.\n\nOption B (focal radiation only) would be insufficient as medulloblastoma requires craniospinal irradiation to address potential microscopic dissemination.\n\nOption C involves reduced-dose craniospinal irradiation with a posterior fossa boost plus chemotherapy, which aligns with current clinical trial approaches for WNT-activated medulloblastoma to maintain efficacy while reducing long-term toxicity.\n\nOption D (observation only) would be inappropriate after only near-total resection, even with favorable biology.\n\nOption E (high-dose chemotherapy with stem cell rescue) would be overly aggressive and typically reserved for recurrent disease or very high-risk cases.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine the best acute reperfusion strategy for this patient, I need to consider several key factors:\n\n1. The patient has a large vessel occlusion (left M1) causing significant symptoms\n2. She is within the time window for reperfusion therapy (70 minutes from onset)\n3. She is on rivaroxaban with her last dose 3 hours ago\n4. Her anti-factor Xa level is elevated at 170 ng/mL, indicating active anticoagulation\n5. She has no contraindications to thrombectomy\n6. The center has neurointerventional capability\n\nIV alteplase (tPA) is contraindicated in patients on direct oral anticoagulants (DOACs) like rivaroxaban with therapeutic anticoagulant activity due to increased bleeding risk. The elevated anti-factor Xa level confirms active anticoagulation.\n\nWhile reversal agents exist (andexanet alfa or 4-factor PCC), there is insufficient evidence supporting their use to enable subsequent thrombolysis in this scenario, and this approach would delay reperfusion.\n\nFor patients with large vessel occlusions on anticoagulation, mechanical thrombectomy is the preferred treatment when IV thrombolysis is contraindicated. This approach provides direct clot removal without increasing hemorrhagic risk.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to evaluate the management of worsening acute chest syndrome (ACS) in a patient with sickle cell disease.\n\nThe patient has:\n- Worsening respiratory status (increased oxygen requirements)\n- Progressive bilateral infiltrates on CXR\n- Already received simple transfusion (Hgb increased from 7.2 to 10.3 g/dL)\n- Not yet intubated but showing clinical deterioration\n\nOption A (Increase simple transfusions): Further simple transfusions would increase viscosity and potentially worsen the condition, especially with Hgb already at 10.3 g/dL.\n\nOption B (Exchange transfusion): For severe or progressive ACS, exchange transfusion is recommended to reduce the percentage of HbS while maintaining adequate oxygen-carrying capacity without increasing blood viscosity.\n\nOption C (High-dose corticosteroids): These are not recommended in ACS and may increase risk of readmission and rebound pain.\n\nOption D (Therapeutic anticoagulation): While pulmonary embolism can be part of ACS, empiric anticoagulation without confirmation is not standard practice.\n\nOption E (Intubation): While the patient may eventually need intubation, addressing the underlying sickling process is the priority at this stage.\n\nGiven the worsening clinical status despite simple transfusion, exchange transfusion to reduce HbS percentage is the most appropriate next step.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "I need to determine the best antiseizure management for this patient with cirrhosis who is experiencing complications while on valproic acid.\n\nKey findings:\n- 58-year-old man with alcohol-related cirrhosis and portal hypertension\n- Current hepatic encephalopathy (confusion, asterixis, elevated ammonia, triphasic waves on EEG)\n- On valproic acid for epilepsy\n- Therapeutic total valproate level but supratherapeutic free valproate level\n- Low serum carnitine\n- No current epileptiform activity on EEG\n\nAnalysis:\n- Valproic acid is problematic in liver disease as it can:\n  1. Be hepatotoxic\n  2. Deplete carnitine\n  3. Have increased free fraction in patients with hypoalbuminemia (common in cirrhosis)\n- The patient's current symptoms are consistent with hepatic encephalopathy, possibly worsened by valproate toxicity\n- The supratherapeutic free valproate level indicates the drug is not properly protein-bound\n- Low carnitine suggests valproate-induced carnitine deficiency\n\nOption B (discontinue valproic acid and start levetiracetam with IV L-carnitine) is most appropriate because:\n- Levetiracetam has minimal hepatic metabolism and is safer in liver disease\n- L-carnitine supplementation addresses the valproate-induced deficiency\n- Discontinuing valproic acid removes a potential contributor to hepatic dysfunction\n\nThe answer is (B)"}]